Kala submits IND for postop cataract surgery agent
January 8th 2014Kala Pharmaceuticals Inc. has submitted an Investigational New Drug (IND) application to the FDA to initiate a phase III clinical program with its mucus-penetrating particle (MPP) technology-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP).
Study: Hydrogel sealant better than sutures
January 1st 2014In a randomly assigned study, including 487 eyes with a leaking clear corneal incision after cataract surgery, closure with a hydrogel sealant was significantly more effective than suturing for preventing fluid egress and was associated with significantly fewer adverse events.
Modular IOL system begins clinical evaluation
January 1st 2014An investigational modular IOL was designed to improve surgeons’ ability to select the right optic the first time, enable safe and easy postoperative enhancement when required, and minimize posterior capsule opacification. A multicenter clinical trial evaluating the IOL was launched in October.
Diabetes still a vision loss problem
January 1st 2014Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study has shown that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only 6 in 10 had their eyes fully examined in the year leading up to the study.
Study: Adalimumab improves refractory pediatric uveitis
December 25th 2013Adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis, according to a study published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus.